Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): Real-world experience. Cabozantinib in patients with locally advanced ...
Bladder cancer caught early is often amenable to treatment, but of course late-stage and aggressive characteristics alter the prognosis for the worse. Understanding high-risk features, including ...
Alterations in the PI3K/Akt signaling pathway and association with outcome in invasive high-grade urothelial cancer (UC). Relationship between high microRNA-200C expression and the risk of death from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback